Eclipse Bioinnovations Inc. (Eclipsebio), a leading provider of sequencing-based analytics for RNA medicines, has announced the acquisition of Terrain Bio, a tech-bio firm specializing in AI/ML-driven RNA design and manufacturing analytics.
Integrating design intelligence with experimental validation
This acquisition marks a strategic move to combine advanced computational capabilities with real-world data verification.
-
Terrain Bio’s expertise: The company has developed sophisticated machine learning models for RNA sequence optimization and an R&D-scale mRNA manufacturing platform that links computational design directly with experimental feedback.
-
Eclipsebio’s foundation: The firm contributes its established sequencing-based datasets and robust quality control platforms, such as eMERGE and eVERSE.
A unified “Design, Make, Test” solution
The combined platform enables RNA therapeutic developers to access a continuous improvement loop:
-
Design: Iteratively optimize RNA constructs using AI modeling and active learning.
-
Test: Measure structures, translation, and impurities through high-resolution sequencing analytics.
-
Manufacture: Gain actionable insights into manufacturing robustness and quality-by-design.
This synergy bridges the gap between computational theory and experimental validation, helping RNA-based medicines reach clinical stages faster and with enhanced confidence.
Source: https://www.contractpharma.com/breaking-news/eclipsebio-acquires-terrain-bio/